Table 2: Adverse events in sunitinib-treated patients classified by age.

Adverse Event Variable p values
Age < 75 years (n = 38) Age ≥ 75 years (n = 9)
All grade ≥ Grade 3 All grade ≥ Grade 3 All grade ≥ Grade 3
Symptoms, n (%)
Nausea 20 (53) 0 (0) 3 (33) 0 (0) 0.2977 -
Fever 16 (42) 0 (0) 3 (33) 0 (0) 0.6297 -
Fatigue 15 (39) 0 (0) 3 (33) 0 (0) 0.7333 -
Anorexia 15 (39) 2 (5) 3 (33) 2 (22) 0.7333 0.1011
Hand-foot syndrome 14 (37) 3 (8) 4 (44) 2 (22) 0.6731 0.2160
Hypertension (de novo) 14 (37) 2 (5) 4 (44) 0 (0) 0.6731 0.4818
Stomatitis 13 (34) 2 (5) 3 (33) 1 (11) 0.9602 0.5187
Diarrhea 10 (26) 0 (0) 3 (33) 1 (11) 0.6722 0.0378
Peripheral edema 6 (16) 0 (0) 2 (22) 0 (0) 0.6443 -
Gastrointestinal hemorrhage 5 (13) 1 (3) 2 (22) 0 (0) 0.4922 0.6228
Abnormal laboratory data, n (%)
AST increased 31 (82) 2 (5) 8 (89) 0 (0) 0.5998 0.4818
ALP increased 25 (66) 1 (3) 6 (67) 0 (0) 0.9602 0.6228
Platelet count decreased 24 (63) 14 (37) 7 (78) 3 (33) 0.4053 0.8438
ALT increased 22 (58) 3 (8) 6 (67) 0 (0) 0.6297 0.3837
Hypothyroidism* 21 (55) 2 (5) 2 (22) 0 (0) 0.0746 0.4818
Creatinine increased 20 (53) 1 (3) 4 (44) 0 (0) 0.8349 0.6382
Neutrophil count decreased 19 (50) 10 (26) 6 (67) 3 (33) 0.3676 0.6722
Leukocyte count decreased 17 (45) 11 (29) 6 (67) 3 (33) 0.2367 0.7959
Hyponatremia 17 (45) 4 (11) 4 (44) 0 (0) 0.9354 0.3019
Blood urea nitrogen increased 16 (42) 1 (3) 5 (56) 0 (0) 0.5060 0.6180
Hypocalcemia 15 (39) 1 (3) 4 (44) 0 (0) 0.7847 0.6228
Hypophosphatemia 14 (37) 4 (11) 2 (22) 0 (0) 0.4053 0.3089
Hyperkalemia 13 (34) 0 (0) 3 (33) 0 (0) 0.9602 -
Gamma-GTP increased 12 (32) 2 (5) 2 (22) 0 (0) 0.5810 0.4818
Serum amylase increased 12 (32) 3 (8) 2 (22) 0 (0) 0.5810 0.3837
Hyperuricemia 12 (32) 0 (0) 2 (22) 0 (0) 0.7132 -
Hypercalcemia 9 (24) 0 (0) 1 (11) 0 (0) 0.4073 -
Hypokalemia 8 (21) 1 (3) 1 (11) 0 (0) 0.4955 0.6228
Lipase Increased 6 (16) 3 (8) 2 (22) 1 (11) 0.6443 0.7559
Total bilirubin increased 6 (16) 0 (0) 2 (22) 0 (0) 0.6443 -

Graded according to CTCAEv3.0, and occurring in at least 20% of patients, or including patients with grade 3 or 4 adverse events. *Hypothyroidism consists of thyroid hormone decreased and thyroid-stimulating hormone increased, and most patients received medication before symptom appearance.